When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
2015; Elsevier BV; Volume: 14; Issue: 3 Linguagem: Inglês
10.1111/jth.13227
ISSN1538-7933
AutoresJerrold H. Levy, Walter Ageno, Noel Chan, Mark Crowther, Peter Verhamme, Jeffrey I. Weitz,
Tópico(s)Acute Ischemic Stroke Management
ResumoThe direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are licensed for stroke prevention in patients with atrial fibrillation and for prevention and treatment of venous thromboembolism 1. As a class, the DOACs are at least as effective as vitamin K antagonists (VKAs) but are associated with less life‐threatening bleeding, particularly intracranial hemorrhage 2. Although all anticoagulants can produce bleeding, the outcomes of major bleeds with DOACs are no worse than those with VKAs even in the absence of clinically available antidotes 3.
Referência(s)